Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020809 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Atezolizumab in Cutaneous Melanoma
A Phase 1 study of Cutaneous Melanoma, sponsored by The Methodist Hospital Research Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04020809: Active Phase 1 study of Cutaneous Melanoma, sponsored by The Methodist Hospital Research Institute.
NCT04020809 is a Phase 1 study of Cutaneous Melanoma that is active but no longer recruiting, run by The Methodist Hospital Research Institute. The registered enrollment target is 20 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04020809, a Phase 1 study of Cutaneous Melanoma, is active but no longer recruiting, sponsored by The Methodist Hospital Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has a higher risk of coming back after surgery (high-risk).
Primary Outcome
Determine the number of participants who complete the 2 neoadjuvant doses of atezolizumab without any extended treatment-related delay (defined as \>80 days from Cycle 1 to date of surgical resection)
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (1)
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
What the registry record for NCT04020809 still lists
NCT04020809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cutaneous Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT04020809 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04020809 about?
NCT04020809 is a clinical study titled "Neoadjuvant Atezolizumab in Cutaneous Melanoma". The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has...
What is the current status of trial NCT04020809?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-09-25. Estimated completion is 2026-10-01.
What conditions does trial NCT04020809 study?
This clinical trial studies the following conditions: Cutaneous Melanoma.
What interventions are being tested in trial NCT04020809?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04020809?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04020809 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04020809's enrollment target sits among peer trials
20 25th of 30 higher than 4 of 30 other Cutaneous Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI